

Biotinylated Human KRAS WT(HLA-A*03:01) Protein

Cat. No. MHC-HM423B

Description

Source	Recombinant Biotinylated Human KRAS WT(HLA-A*03:01) Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.
Accession	NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAGGVGK
Molecular Weight	The protein has a predicted MW of 50.2 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Supplied as 0.22µm filtered solution in PBS (pH 7.4). Please dilute to the desired concentration according to the concentration of the solution shown on the product label.
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.


Assay Data

Tris-Bis PAGE



Biotinylated Human KRAS WT(HLA-A*03:01) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Biotinylated Human KRAS WT(HLA-A*03:01) is greater than 95% as determined by SEC-HPLC.